Outcome of Conservative Therapy in COVID-19 Patients Presenting with Gastrointestinal Bleeding
Abstract Background/Objective There is a paucity of data on the management of gastrointestinal (GI) bleeding in patients with COVID-19 amid concerns about the risk of transmission during endoscopic procedures. We aimed to study the outcomes of conservative treatment for GI bleeding in patients with COVID-19. Methods In this retrospective analysis, 24 of 1342 (1.8%) patients with COVID-19, presenting with GI bleeding from 22 April to 22 July 2020, were included.Results The mean age of patients was 45.8±12.7 years; 17 (70.8%) were males; upper GI (UGI) bleeding: lower GI (LGI) 23:1. Twenty-two (91.6%) patients had evidence of cirrhosis-21 presented with UGI bleeding while one had bleeding from hemorrhoids. Two patients without cirrhosis were presumed to have non-variceal bleeding. The medical therapy for UGI bleeding included vasoconstrictors-somatostatin in 17 (73.9%) and terlipressin in 4 (17.4%) patients. All patients with UGI bleeding received proton pump inhibitors and antibiotics. Packed red blood cells (PRBCs), fresh frozen plasma and platelets were transfused in 14 (60.9%), 3 (13.0%) and 3 (13.0%), respectively. The median PRBCs transfused was 1 (0-3) unit(s). The initial control of UGI bleeding was achieved in all 23 patients and none required an emergency endoscopy. At 5-day follow-up, none rebled or died. Two patients later rebled, one had intermittent bleed due to gastric antral vascular ectasia, while another had rebleed 19 days after discharge. Three (12.5%) cirrhosis patients succumbed to acute hypoxemic respiratory failure during hospital stay.Conclusion Conservative management strategies including pharmacotherapy, restrictive transfusion strategy, and close hemodynamic monitoring can successfully manage GI bleeding in COVID-19 patients and reduce need for urgent endoscopy. The decision for proceeding with endoscopy should be taken by a multidisciplinary team after consideration of the patient’s condition, response to treatment, resources and the risks involved, on a case to case basis..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
bioRxiv.org - (2021) vom: 15. Feb. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shalimar, DM [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| doi: |
10.1101/2020.08.06.20169813 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI018607411 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI018607411 | ||
| 003 | DE-627 | ||
| 005 | 20230429085210.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200827s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.08.06.20169813 |2 doi | |
| 035 | |a (DE-627)XBI018607411 | ||
| 035 | |a (DE-599)biorXiv10.1101/2020.08.06.20169813 | ||
| 035 | |a (biorXiv)10.1101/2020.08.06.20169813 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Shalimar, DM |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Outcome of Conservative Therapy in COVID-19 Patients Presenting with Gastrointestinal Bleeding |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Background/Objective There is a paucity of data on the management of gastrointestinal (GI) bleeding in patients with COVID-19 amid concerns about the risk of transmission during endoscopic procedures. We aimed to study the outcomes of conservative treatment for GI bleeding in patients with COVID-19. Methods In this retrospective analysis, 24 of 1342 (1.8%) patients with COVID-19, presenting with GI bleeding from 22 April to 22 July 2020, were included.Results The mean age of patients was 45.8±12.7 years; 17 (70.8%) were males; upper GI (UGI) bleeding: lower GI (LGI) 23:1. Twenty-two (91.6%) patients had evidence of cirrhosis-21 presented with UGI bleeding while one had bleeding from hemorrhoids. Two patients without cirrhosis were presumed to have non-variceal bleeding. The medical therapy for UGI bleeding included vasoconstrictors-somatostatin in 17 (73.9%) and terlipressin in 4 (17.4%) patients. All patients with UGI bleeding received proton pump inhibitors and antibiotics. Packed red blood cells (PRBCs), fresh frozen plasma and platelets were transfused in 14 (60.9%), 3 (13.0%) and 3 (13.0%), respectively. The median PRBCs transfused was 1 (0-3) unit(s). The initial control of UGI bleeding was achieved in all 23 patients and none required an emergency endoscopy. At 5-day follow-up, none rebled or died. Two patients later rebled, one had intermittent bleed due to gastric antral vascular ectasia, while another had rebleed 19 days after discharge. Three (12.5%) cirrhosis patients succumbed to acute hypoxemic respiratory failure during hospital stay.Conclusion Conservative management strategies including pharmacotherapy, restrictive transfusion strategy, and close hemodynamic monitoring can successfully manage GI bleeding in COVID-19 patients and reduce need for urgent endoscopy. The decision for proceeding with endoscopy should be taken by a multidisciplinary team after consideration of the patient’s condition, response to treatment, resources and the risks involved, on a case to case basis. | ||
| 700 | 1 | |a Vaishnav, Manas |e verfasserin |4 aut | |
| 700 | 1 | |a Elhence, Anshuman |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Ramesh |e verfasserin |4 aut | |
| 700 | 1 | |a Mohta, Srikant |e verfasserin |4 aut | |
| 700 | 1 | |a Palle, Chandan |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Peeyush |e verfasserin |4 aut | |
| 700 | 1 | |a Ranjan, Mukesh |e verfasserin |4 aut | |
| 700 | 1 | |a Vajpai, Tanmay |e verfasserin |4 aut | |
| 700 | 1 | |a Prasad, Shubham |e verfasserin |4 aut | |
| 700 | 1 | |a Yegurla, Jatin |e verfasserin |4 aut | |
| 700 | 1 | |a Dhooria, Anugrah |e verfasserin |4 aut | |
| 700 | 1 | |a Banyal, Vikas |e verfasserin |4 aut | |
| 700 | 1 | |a Agarwal, Samagra |e verfasserin |4 aut | |
| 700 | 1 | |a Bansal, Rajat |e verfasserin |4 aut | |
| 700 | 1 | |a Bhattacharjee, Sulagna |e verfasserin |4 aut | |
| 700 | 1 | |a Aggarwal, Richa |e verfasserin |4 aut | |
| 700 | 1 | |a Soni, Kapil Dev |e verfasserin |4 aut | |
| 700 | 1 | |a Rudravaram, Swetha |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Ashutosh Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Altaf, Irfan |e verfasserin |4 aut | |
| 700 | 1 | |a Choudekar, Avinash |e verfasserin |4 aut | |
| 700 | 1 | |a Mahapatra, Soumya Jagannath |e verfasserin |4 aut | |
| 700 | 1 | |a Gunjan, Deepak |e verfasserin |4 aut | |
| 700 | 1 | |a Kedia, Saurabh |e verfasserin |4 aut | |
| 700 | 1 | |a Makharia, Govind |e verfasserin |4 aut | |
| 700 | 1 | |a Trikha, Anjan |e verfasserin |4 aut | |
| 700 | 1 | |a Garg, Pramod |e verfasserin |4 aut | |
| 700 | 1 | |a Saraya, Anoop |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2021) vom: 15. Feb. |
| 773 | 1 | 8 | |g year:2021 |g day:15 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.08.06.20169813 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 15 |c 02 | ||
| 953 | |2 045F |a 570 | ||